Savara

OverviewSuggest Edit

Savara (also known as Savara Pharmaceuticals) is an orphan lung disease company. It offers Molgradex, a product that is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company also develops AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.

TypePublic
Founded1995
HQAustin, TX, USMap
Websitesavarapharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)39(+19%)
Share Price (Mar 2021)$1.8 (+8%)
Cybersecurity ratingAMore

Key People/Management at Savara

Matthew Pauls

Matthew Pauls

Chairman and CEO
Dave Lowrance

Dave Lowrance

CFO
Badrul Chowdhury

Badrul Chowdhury

CMO
Anne Erickson

Anne Erickson

Senior Vice President, Chief of Staff
Kate McCabe

Kate McCabe

SVP, Legal Affairs
Cecilia Ganslandt

Cecilia Ganslandt

VP, Head of Clinical Development
Show more

Savara Office Locations

Savara has offices in Austin and Hørsholm
Austin, TX, US (HQ)
6836 Bee Caves Rd Building 3, Suite 200
Hørsholm, DK
17 Slotsmarken
Show all (2)

Savara Financials and Metrics

Savara Revenue

Market capitalization (1-Mar-2021)

98.5m

Closing stock price (1-Mar-2021)

1.8
Savara's current market capitalization is $98.5 m.
Show all financial metrics

Savara Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

Learn more about our premium products
SecurityScorecard logo

Savara Online and Social Media Presence

Savara's Trends

Embed Graph

Savara News and Updates

December 10, 2020

Savara Provides Pipeline and Business Update

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial
November 24, 2020

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences
November 11, 2020

Savara to Present at the Jefferies Virtual London Healthcare Conference

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST

 Savara Frequently Asked Questions

  • When was Savara founded?

    Savara was founded in 1995.

  • Who are Savara key executives?

    Savara's key executives are Matthew Pauls, Dave Lowrance and Badrul Chowdhury.

  • How many employees does Savara have?

    Savara has 39 employees.

  • Who are Savara competitors?

    Competitors of Savara include Lung Biotechnology, NanoViricides and ANP Technologies.

  • Where is Savara headquarters?

    Savara headquarters is located at 6836 Bee Caves Rd Building 3, Suite 200, Austin.

  • Where are Savara offices?

    Savara has offices in Austin and Hørsholm.

  • How many offices does Savara have?

    Savara has 2 offices.